← back to search

Neil Vasan

NYU Langone Health · US
Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include PI3K/AKT/mTOR signaling in cancer, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, and Chronic Lymphocytic Leukemia Research.
h-index
18
citations
6,282
works
112
NIH funding
primary concept
Medicine
email

Recent publications

The intrinsic substrate specificity of the human tyrosine kinome
Nature 2024cited by 137position: middledoi
An atlas of substrate specificities for the human serine/threonine kinome
Nature 2023cited by 679position: middledoi
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity
Cancer Cell 2023cited by 92position: middledoi
Data from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
2023cited by 0position: lastdoi
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Nature Reviews Clinical Oncology 2022cited by 171position: firstdoi
Dietary fructose improves intestinal cell survival and nutrient absorption
Nature 2021cited by 268position: middledoi
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Cancer Discovery 2020cited by 275position: middledoi
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Nature Cancer 2020cited by 162position: middledoi
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
Cancer Discovery 2020cited by 70position: middledoi
Phase and context shape the function of composite oncogenic mutations
Nature 2020cited by 47position: middledoi
A view on drug resistance in cancer
Nature 2019cited by 2,678position: firstdoi
Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Science 2019cited by 294position: firstdoi
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Clinical Cancer Research 2014cited by 102position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Lewis C. Cantley · Meyer (China)3 papers (2021–2023)Maurizio Scaltriti · AstraZeneca (Japan)2 papers (2020–2023)Chaitanya Bandlamudi · University of Chicago1 papers (2020–2020)Evan Biederstedt · Broad Institute1 papers (2020–2020) · 1 papers (2023–2023)Katherine E. Hutchinson · Translational Research in Oncology1 papers (2023–2023)Jeffrey S. Ross · SUNY Upstate Medical University1 papers (2023–2023)Samuel Taylor · Tri-Institutional PhD Program in Chemical Biology1 papers (2021–2021)Manish A. Shah · Cornell University1 papers (2021–2021)Shakti Ramsamooj · Cornell University1 papers (2021–2021)Yanyan Cai · Memorial Sloan Kettering Cancer Center1 papers (2020–2020)Timour Baslan · University of Pennsylvania1 papers (2020–2020)José Baselga · Vall d'Hebron Institute of Oncology1 papers (2019–2019)Allison L. Richards · Memorial Sloan Kettering Cancer Center1 papers (2020–2020)Jessica W. Chen · National Institute of Allergy and Infectious Diseases1 papers (2023–2023)Seo‐Kyoung Hwang · Pfizer (United States)1 papers (2021–2021)Roy S. Herbst · Yale New Haven Hospital1 papers (2014–2014)Marcus D. Goncalves · Cornell University1 papers (2021–2021)Andrew J. Dannenberg · BioVentures (United States)1 papers (2021–2021)Smruthy Sivakumar · The University of Texas Health Science Center at Houston1 papers (2023–2023)